Immune Checkpoint Inhibitor Induced Diabetes Mellitus Treated with Insulin and Metformin: Evolution of Diabetes Management in the Era of Immunotherapy

Immune checkpoint inhibitors (ICPIs) are a breakthrough therapy in oncology and have been approved by the Food and Drug Administration for the treatment of several malignancies. ICPIs have been reported to cause immune-mediated damage of islet cells leading to ICPI-induced type 1 diabetes mellitus (...

Descripción completa

Detalles Bibliográficos
Autores principales: Alrifai, Taha, Ali, Faisal Shaukat, Saleem, Sameer, Ruiz, Diana Carolina Miranda, Rifai, Dana, Younas, Sundas, Qureshi, Faisal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875347/
https://www.ncbi.nlm.nih.gov/pubmed/31781446
http://dx.doi.org/10.1155/2019/8781347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875347/
https://www.ncbi.nlm.nih.gov/pubmed/31781446
http://dx.doi.org/10.1155/2019/8781347

Ejemplares similares